SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
...